中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (5): 416-424.doi: 10.35541/cjd.20240155
中华医学会皮肤性病学分会银屑病学组
收稿日期:2024-03-25
修回日期:2024-09-02
发布日期:2025-04-30
通讯作者:
张学军
E-mail:ayzxj@vip.sina.com
Committee on Psoriasis, Chinese Society of Dermatology
Received:2024-03-25
Revised:2024-09-02
Published:2025-04-30
Contact:
Xuejun Zhang
E-mail:ayzxj@vip.sina.com
摘要： 【摘要】 阿普米司特是国内首个获批治疗银屑病的口服靶向小分子药物。阿普米司特特异性靶向磷酸二酯酶4调节炎症平衡的机制，使其可广泛应用于各型银屑病的治疗。多项研究证实，阿普米司特可有效治疗轻、中、重度斑块状银屑病、特殊部位银屑病、关节病型银屑病、掌跖脓疱病及儿童银屑病，且安全性、耐受性好。以阿普米司特的药理作用、治疗银屑病的临床数据等为依据，中华医学会皮肤性病学分会银屑病学组召集相关专家制订本指导意见，目的是规范、合理、安全、有效地使用阿普米司特治疗银屑病。
中华医学会皮肤性病学分会银屑病学组. [开放获取] 阿普米司特治疗银屑病专家指导意见（2025版）[J]. 中华皮肤科杂志, 2025,58(5):416-424. doi:10.35541/cjd.20240155
Committee on Psoriasis, Chinese Society of Dermatology. Expert proposal on apremilast for the treatment of psoriasis （2025 edition）[J]. Chinese Journal of Dermatology, 2025, 58(5): 416-424.doi:10.35541/cjd.20240155
| ［1］ | Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6. |
| ［2］ | 李慧贤, 胡丽, 郑焱, 等. 基于全球疾病负担（GBD）大数据的中国银屑病流行病学负担分析［J］. 中国皮肤性病学杂志, 2021,35（4）:386⁃392. doi: 10.13735/j.cjdv.1001⁃7089.202003197. |
| ［3］ | Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis［J］. Biochem Pharmacol, 2012,83（12）:1583⁃1590. doi: 10.1016/j.bcp.2012.01.001. |
| ［4］ | Li H, Zuo J, Tang W. Phosphodiesterase⁃4 inhibitors for the treatment of inflammatory diseases［J］. Front Pharmacol, 2018,9:1048. doi: 10.3389/fphar.2018.01048. |
| ［5］ | Schett G, Sloan VS, Stevens RM, et al. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases［J］. Ther Adv Musculoskelet Dis, 2010,2（5）:271⁃278. doi: 10.1177/1759720X10381432. |
| ［6］ | Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis［J］. Drugs, 2015,75（12）:1393⁃1403. doi: 10.1007/s40265⁃ 015⁃0439⁃1. |
| ［7］ | Huh KY, Choi Y, Nissel J, et al. Pharmacokinetics and tolerability of apremilast in healthy Korean adult men［J］. Clin Transl Sci, 2021,14（4）:1505⁃1511. doi: 10.1111/cts.13013. |
| ［8］ | Okubo Y, Ohtsuki M, Komine M, et al. Population pharmacokinetic and exposure⁃response analysis of apremilast in Japanese subjects with moderate to severe psoriasis［J］. J Dermatol, 2021,48（11）:1652⁃1664. doi: 10.1111/1346⁃8138. 16068. |
| ［9］ | Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase Ⅲ, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015,173（6）:1387⁃1399. doi: 10.1111/bjd.14164. |
| ［10］ | Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phaseⅢ, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03. 049. |
| ［11］ | Stein Gold L, Papp K, Pariser D, et al. Efficacy and safety of apremilast in patients with mild⁃to⁃moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2022,86（1）:77⁃85. doi: 10.1016/j.jaad.2021.07.040. |
| ［12］ | Stein Gold L, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in systemic⁃ and biologic⁃naive patients with moderate plaque psoriasis: 52⁃week results of UNVEIL［J］. J Drugs Dermatol, 2018,17（2）:221⁃228. |
| ［13］ | Ioannides D, Antonakopoulos N, Chasapi V, et al. A real⁃world, non⁃interventional, prospective study of the effectiveness and safety of apremilast in bio⁃naïve adults with moderate plaque psoriasis treated in the routine care in Greece ⁃ the 'APRAISAL' study［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:2055⁃2063. doi: 10.1111/jdv.18166. |
| ［14］ | Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult⁃to⁃treat nail and scalp psoriasis: results of 2 phaseⅢ randomized, controlled trials （ESTEEM 1 and ESTEEM 2）［J］. J Am Acad Dermatol, 2016,74（1）:134⁃142. doi: 10.1016/j.jaad.2015.09.001. |
| ［15］ | Spencer RK, Elhage KG, Jin JQ, et al. Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta⁃analysis［J］. Dermatol Ther （Heidelb）, 2023,13（2）:437⁃451. doi: 10.1007/s13555⁃022⁃00877⁃w. |
| ［16］ | Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase⁃4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phaseⅡ PSOR⁃005 and phaseⅢ Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis （ESTEEM） clinical trials in patients with moderate to severe psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:99⁃105. doi: 10.1016/j.jaad.2016.02.1164. |
| ［17］ | Merola JF, Parish LC, Guenther L, et al. Efficacy and safety of apremilast in patients with moderate⁃to⁃severe genital psoriasis: results from DISCREET, a phase 3 randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2024,90（3）:485⁃493. doi: 10.1016/j.jaad.2023.10.020. |
| ［18］ | Jonak C, Göttfried I, Perl⁃Convalexius S, et al. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real⁃world in Austria ⁃ results the APPRECIATE study［J］. Ther Adv Chronic Dis, 2023,14:20406223231152785. doi: 10.1177/20406223231152785. |
| ［19］ | Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: results from the EMBRACE randomized trial［J］. J Eur Acad Dermatol Venereol, 2023,37（2）:348⁃355. doi: 10.1111/jdv.18689. |
| ［20］ | Kavanaugh A, Gladman DD, Edwards CJ, et al. Long⁃term experience with apremilast in patients with psoriatic arthritis: 5⁃year results from a PALACE 1⁃3 pooled analysis［J］. Arthritis Res Ther, 2019,21（1）:118. doi: 10.1186/s13075⁃019⁃1901⁃3. |
| ［21］ | Kavanaugh A, Mease PJ, Gomez⁃Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo⁃controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor［J］. Ann Rheum Dis, 2014,73（6）:1020⁃1026. doi: 10.1136/annrheumdis⁃2013⁃205056. |
| ［22］ | Cutolo M, Myerson GE, Fleischmann RM, et al. A phaseⅢ, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial［J］. J Rheumatol, 2016,43（9）:1724⁃1734. doi: 10.3899/jrheum.151376. |
| ［23］ | Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phaseⅢ, randomised, controlled trial （PALACE 3）［J］. Ann Rheum Dis, 2016,75（6）:1065⁃1073. doi: 10.1136/annrheumdis⁃2015⁃207963. |
| ［24］ | Gladman DD, Kavanaugh A, Gómez⁃Reino JJ, et al. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1⁃3 studies［J］. RMD Open, 2018,4（1）:e000669. doi: 10.1136/rmdopen⁃2018⁃000669. |
| ［25］ | Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD⁃naive psoriatic arthritis patients: results of the randomized, placebo⁃controlled PALACE 4 trial［J］. Rheumatology （Oxford）, 2018,57（7）:1253⁃1263. doi: 10.1093/rheumatology/key032. |
| ［26］ | Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy for long⁃term treatment of active psoriatic arthritis in DMARD⁃naïve patients［J］. Rheumatology （Oxford）, 2022,61（3）:1035⁃1043. doi: 10.1093/rheumatology/keab449. |
| ［27］ | Mekhail C, Chouk M, Prati C, et al. Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review［J］. Expert Rev Clin Pharmacol, 2020,13（5）:505⁃519. doi: 10. 1080/17512433.2020.1758556. |
| ［28］ | Torre Alonso JC, Almodóvar González R, Montilla Morales C, et al. Expert recommendations for the use of apremilast in psoriatic arthritis［J］. Reumatol Clin （Engl Ed）, 2023,19（1）:34⁃44. doi: 10.1016/j.reumae.2022.01.001. |
| ［29］ | Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies［J］. Rheumatol Int, 2016,36（5）:603⁃612. doi: 10.1007/s00296⁃016⁃3436⁃0. |
| ［30］ | Terui T, Okubo Y, Kobayashi S, et al. Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: results from a phase 2, randomized, placebo⁃controlled study［J］. Am J Clin Dermatol, 2023,24（5）:837⁃847. doi: 10.1007/s40257⁃023⁃00788⁃2. |
| ［31］ | Kato N, Takama H, Ando Y, et al. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study［J］. Int J Dermatol, 2021,60（5）:570⁃578. doi: 10.1111/ijd.15382. |
| ［32］ | Gioe OA, Savoie C, Grieshaber EB, et al. Treatment of erythrodermic psoriasis with apremilast［J］. JAAD Case Rep, 2021,11:36⁃37. doi: 10.1016/j.jdcr.2021.03.011. |
| ［33］ | Megna M, Ocampo⁃Garza SS, Fabbrocini G, et al. A case of erythrodermic psoriasis successfully treated with apremilast［J］. Dermatol Ther, 2022,35（1）:e15204. doi: 10.1111/dth.15204. |
| ［34］ | Krishnamoorthy G, Kotecha A, Pimentel J. Complete resolution of erythrodermic psoriasis with first⁃line apremilast monotherapy［J］. BMJ Case Rep, 2019,12（1）:e226959. doi: 10.1136/bcr⁃2018⁃226959. |
| ［35］ | Mugheddu C, Pizzatti L, Sanna S, et al. COVID⁃19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:e376⁃e378. doi: 10.1111/jdv.16625. |
| ［36］ | Papadavid E, Kokkalis G, Polyderas G, et al. Rapid clearance of erythrodermic psoriasis with apremilast［J］. J Dermatol Case Rep, 2017,11（2）:29⁃31. doi: 10.3315/jdcr.2017.1246. |
| ［37］ | Olisova OY, Svistunova DA, Anpilogova EM. Apremilast and NB⁃UVB combination therapy in moderate⁃to⁃severe plaque type psoriasis［J］. Int J Womens Dermatol, 2020,6（3）:225. doi: 10. 1016/j.ijwd.2020.03.012. |
| ［38］ | Fazeel ZA, Alhamyani SS, Jain S. Comparison of efficacy and safety of calcipotriol and apremilast combination against cacipotriol monotherapy in psoriasis［J］. Biomed Pharmacol J, 2021,14（4）: 2319⁃2326. doi:10.13005/bpj/2333. |
| ［39］ | Okubo Y, Takahashi H, Hino R, et al. Efficacy and safety of apremilast in the treatment of patients with mild⁃to⁃moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open⁃label, single⁃arm study［J］. Dermatol Ther （Heidelb）, 2022,12（6）:1469⁃1480. doi: 10.1007/s13555⁃022⁃00747⁃5. |
| ［40］ | Hassanandani T, Panda M, Jena AK, et al. Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: a prospective, randomised, assessor⁃blinded, comparative study［J］. Indian J Dermatol Venereol Leprol, 2023,89（2）:213⁃220. doi: 10.25259/IJDVL_843_2021. |
| ［41］ | Arias de la Rosa I, López⁃Montilla MD, Román⁃Rodríguez C, et al. The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast［J］. J Intern Med, 2022,291（5）:676⁃693. doi: 10.1111/joim.13447. |
| ［42］ | Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057. |
| ［43］ | AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study［J］. J Cutan Med Surg, 2016,20（4）:313⁃316. doi: 10.1177/1203475416631328. |
| ［44］ | Takamura S, Sugai S, Taguchi R, et al. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue［J］. J Dermatol, 2020,47（3）:290⁃294. doi: 10. 1111/1346⁃8138.15193. |
| ［45］ | Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate⁃to⁃severe plaque psoriasis: 52⁃week results from a phaseⅢb, randomized, placebo⁃controlled trial （LIBERATE）［J］. J Eur Acad Dermatol Venereol, 2017,31（3）:507⁃517. doi: 10.1111/jdv.14015. |
| ［46］ | Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris ⁃ part 2: specific clinical and comorbid situations［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:281⁃317. doi: 10.1111/jdv.16926. |
| ［47］ | Jiang Y, Chen Y, Yu Q, et al. Biologic and small⁃molecule therapies for moderate⁃to⁃severe psoriasis: focus on psoriasis comorbidities［J］. BioDrugs, 2023,37（1）:35⁃55. doi: 10.1007/s40259⁃022⁃00569⁃z. |
| ［48］ | Ferguson LD, Cathcart S, Rimmer D, et al. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease⁃results of the Immune Metabolic Associations in Psoriatic Arthritis study［J］. Rheumatology （Oxford）, 2022,61（3）:1026⁃1034. doi: 10.1093/rheumatology/keab474. |
| ［49］ | Ikumi K, Torii K, Sagawa Y, et al. Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients［J］. J Dermatol, 2022,49（4）:e125⁃e126. doi: 10.1111/1346⁃8138. 16286. |
| ［50］ | Ikonomidis I, Pavlidis G, Kadoglou N, et al. Apremilast improves endothelial glycocalyx integrity, vascular and left ventricular myocardial function in psoriasis［J］. Pharmaceuticals （Basel）, 2022,15（2）:172. doi: 10.3390/ph15020172. |
| ［51］ | Gelfand JM, Shin DB, Armstrong AW, et al. Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP⁃A phase 4, open⁃label, nonrandomized clinical trial［J］. JAMA Dermatol, 2022,158（12）:1394⁃1403. doi: 10.1001/jamadermatol.2022.3862. |
| ［52］ | Malara G, Politi C, Trifirò C, et al. Effectiveness of apremilast in real life in patients with psoriasis: a longitudinal study［J］. Acta Derm Venereol, 2021,101（9）:adv00545. doi: 10.2340/00015555⁃3846. |
| ［53］ | Danese S, Neurath MF, Kopoń A, et al. Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis［J］. Clin Gastroenterol Hepatol, 2020,18（11）:2526⁃2534.e9. doi: 10.1016/j.cgh.2019. 12.032. |
| ［54］ | Amgen Inc. Labels for NDA 205437. OTEZLA® （apremilast） tablets, for oral use［EB/OL］. （2024⁃04⁃25）［2024⁃12⁃23］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205 437Orig1s013correctedlbl.pdf. |
| ［55］ | Nast A, Spuls PI, van der Kraaij G, et al. European S3⁃Guideline on the systemic treatment of psoriasis vulgaris ⁃ update apremilast and secukinumab ⁃ EDF in cooperation with EADV and IPC［J］. J Eur Acad Dermatol Venereol, 2017,31（12）:1951⁃1963. doi: 10.1111/jdv.14454. |
| ［56］ | Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies［J］. J Am Acad Dermatol, 2020,82（6）:1445⁃1486. doi: 10.1016/j.jaad.2020.02.044. |
| ［57］ | National Institute for Health and Care Excellence. Apremilast for treating moderate to severe plaque psoriasis［EB/OL］. NICE, 2016（2016⁃11⁃23）［2024⁃05⁃15］. https://www.nice.org.uk/guidance/ta419. |
| ［58］ | Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate⁃to⁃severe plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:774⁃790. doi: 10. 1111/jdv.14114. |
| ［59］ | Liu Y, Zhou S, Assaf M, et al. Impact of renal impairment on the pharmacokinetics of apremilast and metabolite M12［J］. Clin Pharmacol Drug Dev, 2016,5（6）:469⁃479. doi: 10.1002/cpdd. 256. |
| ［60］ | Assaf MS, Laille E, Liu L, et al. Pharmacokinetics and safety of apremilast （CC⁃10004） in subjects with hepatic impairment［J］. Int J Med Eng Inform, 2014,6（2）:100. doi: 10.1504/IJMEI.2014. 060246. |
| ［61］ | Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris ⁃ part 1: treatment and monitoring recommendations［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:2461⁃2498. doi: 10.1111/jdv.16915. |
| ［62］ | Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast⁃feeding. The Australasian Psoriasis Collaboration［J］. Australas J Dermatol, 2018,59（2）:86⁃100. doi: 10.1111/ajd.12641. |
| ［63］ | Belinchón I, Velasco M, Ara⁃Martín M, et al. Management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding: a consensus statement［J］. Actas Dermosifiliogr （Engl Ed）, 2021,112（3）:225⁃241. doi: 10.1016/j.ad.2020.10. 002. |
| ［64］ | Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open⁃label study［J］. J Am Acad Dermatol, 2020,82（2）:389⁃397. doi: 10.1016/j.jaad. 2019.08.019. |
| ［65］ | Fiorillo L, Becker E, de Lucas R, et al. Efficacy and safety of apremilast in pediatric patients with moderate⁃to⁃severe plaque psoriasis: 16⁃week results from SPROUT, a randomized controlled trial［J］. J Am Acad Dermatol, 2024,90（6）:1232⁃1239. doi: 10.1016/j.jaad.2023.11.068. |
| ［66］ | Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations［J］. Am J Clin Dermatol, 2019,20（6）:829⁃845. doi: 10.1007/s40257⁃019⁃00457⁃3. |
| ［67］ | Reddy SP, Lee E, Wu JJ. Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus［J］. Cutis, 2019,103（5）:E6⁃E7. |
| ［68］ | Sacchelli L, Patrizi A, Ferrara F, et al. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis［J］. Dermatol Ther, 2018,31（6）:e12719. doi: 10.1111/dth.12719. |
| ［69］ | Shah BJ, Mistry D, Chaudhary N. Apremilast in people living with HIV with psoriasis vulgaris: a case report［J］. Indian J Dermatol, 2019,64（3）:242⁃244. doi: 10.4103/ijd.IJD_633_18. |
| ［70］ | Zarbafian M, Cote B, Richer V. Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long⁃term treated HIV infection: a case report［J］. SAGE Open Med Case Rep, 2019,7:2050313X19845193. doi: 10.1177/2050313X19845193. |
| ［71］ | Pullamsetti SS, Banat GA, Schmall A, et al. Phosphodiesterase⁃4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF［J］. Oncogene, 2013,32（9）:1121⁃1134. doi: 10.1038/onc.2012.136. |
| ［72］ | Bernardini N, Skroza N, Marchesiello A, et al. Psoriatic patients with a history of cancer: a real⁃life experience with apremilast treatment for 104 weeks［J］. Dermatol Ther, 2022,35（10）:e15306. doi: 10.1111/dth.15306. |
| ［73］ | Di Lernia V, Casanova DM, Ricci C. Apremilast in patients with history of malignancy: a real⁃life, single⁃center experience［J］. Int J Dermatol, 2021,60（1）:e22⁃e24. doi: 10.1111/ijd.15093. |
| ［74］ | Apalla Z, Psarakis E, Lallas A, et al. Psoriasis in patients with active lung cancer: is apremilast a safe option?［J］. Dermatol Pract Concept, 2019,9（4）:300⁃301. doi: 10.5826/dpc.0904a11. |
| ［75］ | Kurata M, Ohyama M. Long⁃term remission of severe nail psoriasis after discontinuation of apremilast in a colorectal cancer survivor［J］. J Dermatol, 2021,48（6）:e248⁃e249. doi: 10.1111/1346⁃8138.15831. |
| ［76］ | Foti C, Tucci M, Stingeni L, et al. Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma［J］. Dermatol Ther, 2021,34（1）:e14653. doi: 10.1111/dth.14653. |
| ［77］ | Peitsch WK. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab［J］. J Dtsch Dermatol Ges, 2019,17（3）:330⁃332. doi: 10.1111/ddg. 13771. |
| ［78］ | 上海市医学会皮肤性病学分会, 上海市医学会肿瘤靶分子专科分会. 抗肿瘤药物相关皮肤不良反应管理专家共识［J］. 中华皮肤科杂志, 2023,56（10）:907⁃919. doi: 10.35541/cjd.2023 0084. |
| ［79］ | Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors⁃derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement［J］. J Eur Acad Dermatol Venereol, 2022,36（3）:332⁃350. doi: 10. 1111/jdv.17855. |
| ［80］ | 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1033⁃1047. doi: 10.35541/cjd.20210643. |
| ［81］ | Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty［J］. Arthritis Care Res （Hoboken）, 2022,74（9）:1399⁃1408. doi: 10.1002/acr.24893. |
| ［82］ | Albrecht K, Poddubnyy D, Leipe J, et al. Perioperative management of patients with inflammatory rheumatic diseases: updated recommendations of the German Society for Rheumatology［J］. Z Rheumatol, 2023,82（Suppl 1）:1⁃11. doi: 10.1007/s00393⁃021⁃01150⁃9. |
| ［83］ | Ghislain PD, Lambert J, Lam Hoai XL, et al. Real⁃life effectiveness of apremilast for the treatment of psoriasis in Belgium: results from the observational OTELO study［J］. Adv Ther, 2022,39（2）:1068⁃1080. doi: 10.1007/s12325⁃021⁃01981⁃7. |
| ［84］ | Koskivirta I, Ruotsalainen J, Kurki S, et al. Real⁃world registry⁃based study on apremilast use in psoriasis and psoriatic arthritis in Finland［J］. Scand J Rheumatol, 2023,52（5）:549⁃555. doi: 10.1080/03009742.2022.2151109. |
| ［85］ | Crowley J, Thaçi D, Joly P, et al. Long⁃term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials （ESTEEM 1 and 2）［J］. J Am Acad Dermatol, 2017,77（2）:310⁃317.e1. doi: 10.1016/j.jaad.2017.01.052. |
| ［86］ | Mease PJ, Hatemi G, Paris M, et al. Apremilast long⁃term safety up to 5 years from 15 pooled randomized, placebo⁃controlled studies of psoriasis, psoriatic arthritis, and Behçet's syndrome［J］. Am J Clin Dermatol, 2023,24（5）:809⁃820. doi: 10.1007/s40257⁃023⁃00783⁃7. |
| ［87］ | Langley A, Beecker J. Management of common side effects of apremilast［J］. J Cutan Med Surg, 2018,22（4）:415⁃421. doi: 10.1177/1203475417748886. |
| ［88］ | Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity［J］. Cell Signal, 2014,26（9）:2016⁃2029. doi: 10.1016/j.cellsig.2014. 05.014. |
| ［89］ | Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis［J］. Am J Clin Dermatol, 2018,19（1）:23⁃32. doi: 10.1007/s40257⁃017⁃0302⁃0. |
| ［90］ | Speeckaert R, Lambert J, Puig L, et al. Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS⁃Cov⁃2 vaccination strategies?［J］. Drugs R D, 2021,21（3）:341⁃350. doi: 10.1007/s40268⁃021⁃00349⁃0. |
| [1] | 白璐 楚妍 刘园园 朱才勇. 慢性手部湿疹的治疗进展[J]. 中华皮肤科杂志, 2025, 58(5): 477-480. |
| [2] | 李紫钰 鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025, 58(4): 378-383. |
| [3] | 中国医师协会皮肤科医师分会儿童学组 中华医学会皮肤性病学分会银屑病学组. 【开放获取】 儿童脓疱型银屑病诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 297-306. |
| [4] | 何春霞 晋红中. 【开放获取】 急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025, 58(4): 307-314. |
| [5] | 许焯红 胡煜 顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 0(3): 20220881-e20220881. |
| [6] | 王文秋 李承新 王睿. 生物制剂治疗银屑病复发的研究现状[J]. 中华皮肤科杂志, 2025, 0(3): 20230301-e20230301. |
| [7] | 李秀珍 徐秀莲. 白细胞介素23抑制剂治疗对银屑病共病的影响[J]. 中华皮肤科杂志, 2025, 58(3): 268-272. |
| [8] | 陈良宏 孙艳 王敬玉 吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 266-268. |
| [9] | 金兰 邱云 王唯嘉 康晓静 丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52. |
| [10] | 王博 郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75. |
| [11] | 陈嘉琪 张禁 唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 84-88. |
| [12] | 乔嘉熙 夏萍 陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829. |
| [13] | 林子沅 庞天怡 武静文 靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 765-769. |
| [14] | 窦进法 王建波 张帅 李建国 刘鸿伟 张守民. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析：单中心横断面研究[J]. 中华皮肤科杂志, 2024, 57(8): 739-742. |
| [15] | 隋长霖 常晓 赵琪 朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 570-574. |
|
||
